TABLE 4.
Base case change in eNPV (thousands 2023 USD) and ROI per phase II investigational indication for digital endpoint clinical trials by therapeutic area.
| Therapeutic area | Reduction in phase duration (months) | Reduction in trial size (%) | Mean implementation cost | Median implementation cost | ||
|---|---|---|---|---|---|---|
| eNPV delta | ROI | eNPV delta | ROI | |||
| Cardiovascular | 4 | 11.0 | $2214 | 0.324x | $5983 | 3.0x |
| CNS | 4 | 13.9 | $2086 | 0.305x | $5797 | 2.9x |
| Diabetes | 3 | 16.4 | $3256 | 0.477x | $6967 | 3.5x |
Note: Mean implementation cost (thousands 2023 USD) per trial = $3416; median implementation cost (thousands 2023 USD) per trial = $1000. Costs and returns discounted to the start of phase II testing. ROI = eNPV/sponsor implementation cost per indication (assumes two phase II trials per indication).